Manipulating Metabolism: Lilly Links With UK Biotech Sitryx
Pair Will Act On Intracellular Metabolic Pathways To Modify Diseases
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
You may also be interested in...
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.